Yanyi Xiao Selected Research

Neoplasms (Cancer)

3/2022	Inhibition of STAT3Y705 phosphorylation by Stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells.
1/2022	Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer.
1/2022	The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
12/2021	The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism.
11/2021	Fisetin inhibits the proliferation, migration and invasion of pancreatic cancer by targeting PI3K/AKT/mTOR signaling.
1/2021	Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways.
1/2021	Inhibition of proliferation-linked signaling cascades with atractylenolide I reduces myofibroblastic phenotype and renal fibrosis.
1/2021	The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation.
1/2019	Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yanyi Xiao Research Topics

Disease

9	Neoplasms (Cancer) 03/2022 - 01/2019
8	Pancreatic Neoplasms (Pancreatic Cancer) 10/2023 - 01/2021
6	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2019
3	Adenocarcinoma 12/2021 - 01/2021
2	Carcinogenesis 03/2022 - 01/2019
2	Fibrosis (Cirrhosis) 01/2021 - 12/2019
2	Endometrial Neoplasms (Endometrial Cancer) 01/2019 - 01/2018
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Hypoxia (Hypoxemia) 01/2021
1	Ureteral Obstruction 12/2019

Drug/Important Bio-Agent (IBA)

4	CateninsIBA 04/2022 - 01/2019
3	Gemcitabine FDA Link 04/2022 - 01/2021
2	Niclosamide FDA Link 04/2022 - 01/2022
2	AnthelminticsIBA 04/2022 - 01/2022
2	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 01/2021
2	AntioxidantsIBA 11/2021 - 01/2021
1	chloroxine FDA Link 10/2023
1	Antineoplastic Agents (Antineoplastics)IBA 10/2023
1	Sincalide FDA Link 10/2023
1	statticIBA 03/2022
1	sophocarpineIBA 01/2022
1	puerarinIBA 12/2021
1	FlavonoidsIBA 12/2021
1	IsoflavonesIBA 12/2021
1	fisetinIBA 11/2021
1	atractylenolide IIBA 01/2021
1	fraxetinIBA 01/2021
1	ColivelinIBA 01/2021
1	QuercetinIBA 01/2021
1	Cadherins (E-Cadherin)IBA 01/2021
1	ResveratrolIBA 12/2019
1	cinobufotalinIBA 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 01/2019
1	hepatoma-derived growth factorIBA 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Endoplasmic Reticulum Chaperone BiPIBA 01/2018

Therapy/Procedure

1	Castration 01/2022
1	Drug Therapy (Chemotherapy) 01/2022